Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 6/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 4/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | USP2 | O75604 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375286 | 0.85 | JAK3 (0.38) | HRH3CYP2D6JAK3KMT2A | |
| SCHEMBL16380252 | 0.82 | USP2 (0.44) | CYP2D6CYP1A2CYP2C9ALDH1A1TSHR | |
| SCHEMBL29724136 | 0.81 | GRM5 (0.47) | CYP2D6CYP1A2CYP2C9ALDH1A1HIF1A | |
| SCHEMBL24854333 | 0.81 | HRH3 (0.46) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL16375281 | 0.79 | CYP2D6 (0.41) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL23686509 | 0.78 | JAK3 (0.38) | CYP2D6CYP1A2CYP2C9ALDH1A1TSHR | |
| SCHEMBL25228712 | 0.76 | JAK3 (0.43) | CYP2D6CYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL22296240 | 0.76 | CYP3A4 (0.55) | CYP2D6CYP1A2CYP2C9ALDH1A1TSHR | |
| SCHEMBL16380178 | 0.76 | GRM5 (0.41) | CYP2D6CYP1A2CYP2C9ALDH1A1HIF1A | |
| SCHEMBL25870417 | 0.76 | KMT2A (0.43) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, PRKACA | HRH3 3109/4885CYP2D6 3779/4885CYP1A2 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.